Roche
Roche buoyed by 6% sales growth
October 22, 2015Sales and Marketing Roche, financial results
Roche has reported strong sales growth for the first nine months of 2015 and revised its sales outlook to reflect …
Positive late-stage results for Genentech’s ocrelizumab in different forms of MS
October 8, 2015Research and Development ECTRIMS, Genentech, MS, Roche, multiple sclerosis, ocrelizumab
Roche’s biotech arm Genentech has presented ‘transformative’ data at an international multiple sclerosis conference on its investigational drug ocrelizumab. Ocrelizumab …
Genentech’s ocrelizumab shows efficacy in phase III trial
September 30, 2015Research and Development Genentech, MS, Roche, ocrelizumab
Roche subsidiary Genentech has announced positive results from a pivotal phase III study of its investigational medicine ocrelizumab in people …
Roche says Esbriet shown to extend lives of IPF patients
September 30, 2015Medical Communications, Research and Development, Sales and Marketing Esbriet, Roche, idiopathic pulmonary fibrosis
Roche has presented new clinical data and abstracts on Esbriet (pirfenidone) in the treatment of idiopathic pulmonary fibrosis (IPF), showing …
Roche to present new Esbriet data at ERS Congress 2015
September 21, 2015Research and Development, Sales and Marketing Esbriet, European Respiratory Congress, Roche, idiopathic pulmonary fibrosis, pirfenidone
Roche has announced it will present new data analyses of Esbriet in idiopathic pulmonary fibrosis (IPF) at the European Respiratory …
Cancer Drugs Fund ‘not sustainable in current form’
September 17, 2015CDF, Cancer Drugs Fund, Department of Health, NHS England, National Audit Office, Public Accounts Committe, Roche, avastin
The Cancer Drugs Fund has improved access to treatments, although the UK still lags behind other countries despite its ‘unsustainable’ …
New treatment option for ovarian cancer patients in Scotland
September 8, 2015Medical Communications, Research and Development, Sales and Marketing Roche, Scotland, avastin, ovarian cancer
The Scottish Medicines Consortium (SMC) has approved the use of Avastin in combination with paclitaxel chemotherapy as a treatment for women …
Genentech Haemophilia therapy gets FDA breakthrough designation
September 4, 2015Research and Development, Sales and Marketing Genentech, Roche, haemophilia a
Roche subsidiary Genentech has been granted FDA breakthrough therapy designation for its ACE910 (RG6013, RO5534262) haemophilia A therapy. The designation …
Roche lung cancer therapy succeeds in mid-stage trial
August 17, 2015Research and Development, Sales and Marketing Genentech, Roche, atezolizumab, lung cancer, non-small cell lung cancer
Roche’s biotech arm Genentech has scored positive results in a pivotal Phase II study of its investigational cancer immunotherapy atezolizumab. …
Abbvie and Roche report success in Phase II leukaemia trial
August 13, 2015Research and Development AbbVie, Breakthrough Therapy Designation, CLL, EMA, FDA, Roche, chronic lymphocytic leukaemia, leukaemia, venetoclax
AbbVie plans to submit regulatory applications for its leukaemia drug venetoclax to the FDA and the EMA before the end …
Eleven companies accused in Romanian corruption probe
August 3, 2015Business Services, Medical Communications, Sales and Marketing China, Daily Telegraph, GSK, Roche, Romania, bribery, corruption
GSK and Roche are among eleven pharma firms being investigated for paying bribes to doctors in Romania to prescribe drugs. …
Cancer and immunology drugs drive strong Roche sales performance
July 23, 2015Sales and Marketing Roche, Severin Schwan, financials
Sales at Roche rose 6% in the first half of 2015, buoyed by “significant growth of sales and immunology medicines”, …
Lilly, Biogen and Roche debut Alzheimer’s disease drug results
July 22, 2015Research and Development Alzheimer's, Alzheimer's disease, Biogen, Conference, Eli Lilly, Roche, lilly
Big pharma companies have posted mixed results in trials of several potential new treatments for Alzheimer’s disease. But the results, …
Roche posts positive mid-stage trial results for atezolizumab
July 13, 2015Research and Development Genentech, PD-L1, Phase II, Roche, anti-PD-L1, atezolizumab, clinical trial, immuno-oncology, personalised medicine
A cancer drug in development by Roche has performed well in a mid-phase clinical trial – prompting the Swiss firm …
NICE wants more answers from Gilead on Zydelig
June 18, 2015Sales and Marketing Gilead, MabThera, NICE, Roche, UK, brett wells, zydelig
The National Institute for Health and Care Excellence has not recommended Gilead’s leukaemia drug Zydelig in draft guidance. But the …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
